Results 161 to 170 of about 80,637 (252)

Nivolumab after recurrent pembrolizumab-associated hepatotoxicity in PD-L1-high metastatic squamous non-small cell lung cancer: a case report. [PDF]

Oxf Med Case Reports
Bowen A, Wendel K, Saleem MD, Lin Z, Thulluri R, Hrinczenko B.   +5 more
europepmc   +1 more source

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Borghaei H, Balli D, Paz-Ares LG, Reck M, Lu S, Ramalingam SS, Brahmer JR, John T, Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Zurawski B, Pluzanski A, Lee JS, Agrawal S, Spires T, Neely J, Ip V, Eccles LJ, Chang H, Szustakowski JD, Bhatia S, Yadav A, Eddy N, Geese WJ, O'Byrne KJ.   +26 more
europepmc   +1 more source

Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Systemic treatment of cutaneous melanoma has changed since 2011, with clinical studies demonstrating improved outcomes. This analysis evaluated whether this improvement is evident in a real‐world cohort, focusing on overall survival (OS) and relapse‐free survival (RFS).
Lena Nanz, Claus Garbe, Markus Reitmajer, Andrea Forschner, Yves Maczey‐Leber, Teresa Amaral, Lukas Flatz, Ulrike Leiter   +7 more
wiley   +1 more source

Prognostic Value of the Lung Immune Prognostic Index and an ECOG-Albumin-LIPI Nomogram in Metastatic NSCLC Patients Treated with Second- or Third-Line Nivolumab. [PDF]

J Clin Med
Divriklioğlu D, Bayrakçı İ, Bakır Kahveci G, Gökmen İ, Koç DY, Demirdelen E, Küçükarda A, Hacıoğlu MB, Erdoğan B, Topaloğlu S.   +9 more
europepmc   +1 more source

Nivolumab Induced Reactivation of Hepatitis B in a Patient with Metastatic Gastric Adenocarcinoma-A Case Report. [PDF]

Reports (MDPI)
Kaur JN, Padhi P, Dodeja A.
europepmc   +1 more source

Clinical Outcomes of Gradual Corticosteroid Tapering for Immune Checkpoint Inhibitor‐Induced Liver Injury

Hepatology Research, EarlyView.
Patients with severe ICI‐induced liver injury are commonly treated with corticosteroids, but the optimal tapering strategy remains uncertain. In this study, a gradual corticosteroid tapering strategy based partly on Japanese clinical practice for autoimmune hepatitis was associated with a low rate of relapse and enabled many patients to safely resume ...
Naoto Soma, Yoshihito Uchida, Kayoko Sugawara, Masamitsu Nakao, Nobuaki Nakayama, Yukinori Imai, Suguru Mizuno, Satoshi Mochida   +7 more
wiley   +1 more source

Immune Checkpoint Inhibitor-Induced Vogt-Koyanagi-Harada-like Disease Complicated by Inflammatory Macular Neovascularisation: A Case Report and Literature Review. [PDF]

Diagnostics (Basel)
Papavasileiou ME, Stavrakas P, Mitri P, Kalaitzakis P, Makris G, Ragkousis A.   +5 more
europepmc   +1 more source

The Imbalance Between Tumor Immunosurveillance and Tumor Immune Escape in Glioblastoma

Immunology &Cell Biology, EarlyView.
(Left)The identification and elimination of tumour cells is enabled by the infiltration of functional innate and adaptive immune effectors into the TME, such as natural killer cells (NK cells) and cytotoxic T cells (CD8 T cells). Effective innate and adaptive immune responses facilitate immunological control of malignant outgrowth.
Sarah J. MacDonald, Matthew Drill, Padmakrishnan C. Jayakrishnan, Richard P. Sequeira, Terence J. O'Brien, Rosalind L. Jeffree, Mastura Monif   +6 more
wiley   +1 more source

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies. [PDF]

Diabetes Care
Chen LR, Cooksley T, Kochhar R, Titus Raj EJ, Lorigan P, Adam S.   +5 more
europepmc   +1 more source

Five‐year survival impact of adjuvant anti‐PD‐1 therapy in a nationwide cohort of stage III melanoma

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This nationwide real‐world cohort study was unable to demonstrate a population‐level survival benefit of adjuvant anti‐PD‐1 in stage III melanoma. Matched analyses suggested higher OS in treated patients. However, limited statistical power and potential residual confounding preclude firm conclusions.
Marie B. Weitemeyer, Neel M. Helvind, Shawez Khan, Pernille Bidstrup, Karina D. Steffensen, Adam Andrzej Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Marco Donia, Lisbet R. Hölmich, Eva Ellebaek   +11 more
wiley   +1 more source